Ulcerative Colitis

In the second half of 2023, there were numerous landmark FDA approvals for gastroenterology and hepatology, in particular for the treatment of ulcerative colitis, with four new options squeezing into an already saturated market.

The AGA has published the first comprehensive guideline on the management of pouchitis and other inflammatory pouch disorders among patients with ulcerative colitis who have undergone ileal pouch-anal anastomosis surgery.

Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.

In this episode of Meeting Mic, we bring you Healio’s top headlines from ACG 2023.

VANCOUVER, British Columbia — Researchers found significant associations between state-level health disparities and poor inflammatory bowel disease-related outcomes, with low-ranking states demonstrating higher mortality rates.

VANCOUVER, British Columbia — Patients with ulcerative colitis were more likely to achieve clinical response and steroid-free clinical remission at 8 to 16 weeks on upadacitinib vs. ustekinumab, according to a presenter.

The FDA has approved Wezlana as a Stelara biosimilar for the treatment of plaque psoriasis, psoriatic arthritis and other inflammatory diseases, according to an FDA press release.

VANCOUVER, British Columbia — In this Healio video exclusive, Neslyne B. Augustin, MD, reviews the case of a patient with ulcerative colitis and concomitant SARS-CoV-2 infection, which she presented at the ACG Annual Scientific Meeting.

VANCOUVER, British Columbia — A post hoc analysis of the ELEVATE UC trials demonstrated “rapid treatment effect” with early symptomatic response among patients treated with etrasimod for ulcerative colitis, according to a presenter.

Newly diagnosed psoriatic disease may bring with it a significantly increased risk for autoimmune disease incidences, according to a study.